Bradley M Lunde

Title: The Innovative Contributions of Bradley M. Lunde

Introduction

Bradley M. Lunde is a prominent inventor based in Lebanon, NH (US), known for his significant contributions to the field of cancer therapy. With a total of 10 patents to his name, Lunde has made remarkable strides in developing multi-specific binding proteins that target cancer cells.

Latest Patents

Lunde's latest patents focus on multi-specific binding proteins that bind to B-cell maturation antigen (BCMA), NKG2D, and CD16. These proteins are designed to kill human cancer cells effectively. The patents describe pharmaceutical compositions and therapeutic methods that are particularly useful for treating cancers that express BCMA. The multi-specific binding proteins exhibit high potency and maximum lysis of target cells compared to traditional anti-BCMA monoclonal antibodies. Additionally, Lunde has developed a cancer therapy that combines an anti-PD1 antibody with a multi-specific binding protein that binds to a tumor-associated antigen, NKG2D receptor, and CD16. This combination therapy aims to enhance the effectiveness of cancer treatment.

Career Highlights

Lunde is currently associated with Dragonfly Therapeutics, Inc., where he continues to innovate in the field of cancer research. His work has been instrumental in advancing therapeutic methods that improve patient outcomes in cancer treatment.

Collaborations

Lunde collaborates with notable colleagues such as Gregory P. Chang and Ann F. Cheung, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Bradley M. Lunde's work in developing multi-specific binding proteins represents a significant advancement in cancer therapy. His innovative approach and dedication to research continue to impact the field positively.